Buscar





Buscar





Mercado
/
Acciones
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX

Añadir a la lista de seguimiento

42.650USD

+0.110+0.26%

Cierre 05/13, 16:00（ET）Cotizaciones retrasadas 15 min

6.62BCap. mercado

13.32P/E TTM



TG Therapeutics Inc

42.650

+0.110+0.26%

Descripción general Finanzas Discusiones Análisis Compañía

Descripción general

Finanzas

Discusiones

Análisis

Compañía

Más Datos de TG Therapeutics Inc Compañía

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Información de TG Therapeutics Inc



Símbolo de cotizaciónTGTX

Nombre de la empresaTG Therapeutics Inc

Fecha de salida a bolsaDec 14, 1995

Director ejecutivoWeiss (Michael S)

Número de empleados338

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 14

Dirección3020 Carrington Mill Blvd., Suite 475

CiudadMORRISVILLE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal27560-5435

Teléfono18775758489

Sitio Webhttps://www.tgtherapeutics.com/

Símbolo de cotizaciónTGTX

Fecha de salida a bolsaDec 14, 1995

Director ejecutivoWeiss (Michael S)

Ejecutivos de TG Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

9.78M

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

690.61K

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

Dr. Yann Echelard

Independent Director

223.82K

Mr. Daniel Hume, J.D.

Independent Director

192.75K

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

179.69K

Dr. Sagar Lonial

Independent Director

94.06K

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

9.78M

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

690.61K

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

Dr. Yann Echelard

Independent Director

223.82K

Mr. Daniel Hume, J.D.

Independent Director

192.75K

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

179.69K

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q1

FY2024

Por negocioUSD

Nombre

Ganancia

Proporción

Total product revenue, net

606.93M

98.48%

Royalty Revenue

5.62M

0.91%

Other Revenue

3.59M

0.58%

License Revenue

152.00K

0.02%

Milestone Revenue

0.00

0.00%

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Total product revenue, net

606.93M

98.48%

Royalty Revenue

5.62M

0.91%

Other Revenue

3.59M

0.58%

License Revenue

152.00K

0.02%

Milestone Revenue

0.00

0.00%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

12.51%

Weiss (Michael S)

6.39%

State Street Investment Management (US)

5.54%

Vanguard Portfolio Management, LLC

5.40%

Vanguard Capital Management, LLC

4.31%

Otro

65.85%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

12.51%

Weiss (Michael S)

6.39%

State Street Investment Management (US)

5.54%

Vanguard Portfolio Management, LLC

5.40%

Vanguard Capital Management, LLC

4.31%

Otro

65.85%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

37.18%

Investment Advisor/Hedge Fund

19.01%

Hedge Fund

8.02%

Individual Investor

7.47%

Research Firm

3.77%

Pension Fund

1.23%

Bank and Trust

0.50%

Family Office

0.22%

Insurance Company

0.03%

Otro

22.56%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

760

122.50M

80.02%

+4.40M

2025Q4

733

103.04M

64.90%

-17.74M

2025Q3

698

101.46M

63.91%

-17.24M

2025Q2

693

115.94M

73.03%

-21.56M

2025Q1

704

116.82M

73.80%

-25.76M

2024Q4

657

113.87M

72.65%

-36.14M

2024Q3

598

117.83M

76.11%

-20.28M

2024Q2

544

109.58M

70.90%

-28.91M

2024Q1

535

105.41M

68.45%

-29.01M

2023Q4

542

104.64M

69.13%

-36.73M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

19.14M

11.99%

+312.14K

+1.66%

Dec 31, 2025

Weiss (Michael S)

9.78M

6.12%

+622.00K

+6.79%

Jan 08, 2026

State Street Investment Management (US)

8.48M

5.31%

+379.38K

+4.68%

Dec 31, 2025

ClearBridge Investments, LLC

3.45M

2.16%

-1.20M

-25.76%

Dec 31, 2025

Geode Capital Management, L.L.C.

3.40M

2.13%

-40.05K

-1.16%

Dec 31, 2025

Soleus Capital Management, L.P.

3.14M

1.97%

-705.42K

-18.35%

Dec 31, 2025

Congress Asset Management Company, LLP

1.92M

1.2%

+922.41K

+92.24%

Dec 31, 2025

Pictet Asset Management Ltd.

1.46M

0.91%

-148.50K

-9.23%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco S&P SmallCap Health Care ETF

2.89%

State Street SPDR S&P Biotech ETF

1.93%

Virtus LifeSci Biotech Products ETF

1.49%

Invesco S&P SmallCap 600 Pure Growth ETF

1.44%

Invesco S&P SmallCap Momentum ETF

1.4%

Direxion Daily S&P Biotech Bull 3X Shares

1.11%

State Street SPDR S&P 600 Small Cap Growth ETF

0.65%

First Trust NASDAQ Pharmaceuticals ETF

0.63%

Principal U.S. Small-Cap ETF

0.62%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.61%

Invesco S&P SmallCap Health Care ETF

Proporción2.89%

State Street SPDR S&P Biotech ETF

Proporción1.93%

Virtus LifeSci Biotech Products ETF

Proporción1.49%

Invesco S&P SmallCap 600 Pure Growth ETF

Proporción1.44%

Invesco S&P SmallCap Momentum ETF

Proporción1.4%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción1.11%

State Street SPDR S&P 600 Small Cap Growth ETF

Proporción0.65%

First Trust NASDAQ Pharmaceuticals ETF

Proporción0.63%

Principal U.S. Small-Cap ETF

Proporción0.62%

Vanguard S&P Small-Cap 600 Growth Index Fund

Proporción0.61%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

